Daiichi Sankyo loses bid to bat back a $42M patent verdict over Enhertu
After a jury awarded Seagen nearly $42 million and found Daiichi Sankyo infringed on its patent in the development of Enhertu, Daiichi appealed the decision to try to stop the verdict’s enforcement. But the company found no luck there, either.
Daiichi Sankyo lost a challenge to the ruling Tuesday, as the Eastern District Court of Texas disagreed with its claims that the patent involved couldn’t be enforced. Judge Rodney Gilstrap upheld the previous decision, which found Daiichi willfully infringed on patents related to Seagen’s antibody-drug conjugate technology in creating Enhertu.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
